Atlas Trials

FMS-like Tyrosine Kinase-3 (FLT3) Mutations

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch FMS-like Tyrosine Kinase-3 (FLT3) Mutations

RecordFirmDate
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (NCT03070093)Astellas Pharma Global Development, Inc.

Track FMS-like Tyrosine Kinase-3 (FLT3) Mutations automatically

Every clearance here is in the API, with alerts when new ones post.